Table of Contents Table of Contents
Previous Page  310 / 812 Next Page
Information
Show Menu
Previous Page 310 / 812 Next Page
Page Background

S306

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.658

EW541

Quality of Life Assessment in

schizophrenia - development of a

short version of the QLiS

M. Franz

1 ,

, T . S

enin

2 , T. M

eyer

2

1

Vitos Klinik Kurhessen, Vitos Klinik Kurhessen, Bad Emstal, Germany

2

Institute of epidemiology- social medicine and health services

research, Integrative rehabilitation research unit, Hannover, Germany

Corresponding author.

The QLiS (Quality of Life in Schizophrenia) is a disease-specific

questionnaire with high content validity and sound psychometric

properties. It comprises 54 items related to 12 subscales. However,

its use in surveys or clinical studies is limited due to its length. Our

aim was to develop and validate a short form of the QLiS.

Four steps were taken to develop the short form (QLiS-SF) using

samples from the Clinical Analysis of the Treatment of Schizophre-

nia study. 1. Amodel with second order scales was developed using

exploratory factor analysis. 2. The resulting model was tested in

an independent sample using confirmative factor analysis (CFA).

3. Based on this model, items were selected on grounds of dis-

tributional properties, content reviews, and item loadings. 4. The

resulting short form was validated independently through CFA.

Results

Three second order scales were constructed: illness-

related quality of life, social life, and global subjective well-being.

CFA of the new theoretical model resulted in a CFI of 0.67 and abso-

lute fit indices of CMIN/df = 2.55, RMSEA = 0.08, SRMR = 0.09. We

selected 13 items that showed good statistical properties and good

fit of content to subscale. Fit of the underlying theoretical model

with the 13 items was satisfactory (CFI = 0.95, CMIN/df = 2.23,

RMSEA = 0.06, SRMR = 0.04). Composite reliability scores for the

three subscales were above 0.70.

The QLiS-SF showed adequate model fit and reliability. It offers a

novel, well-founded opportunity to assess quality of life in persons

with schizophrenia in situations in which the application of the

long version is not considered possible.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.659

EW542

The relationship between childhood

trauma and theory of mind in

schizophrenia

J. Mrizak

, R. Trabelsi , A. Arous , A. Aissa , H. Ben Ammar ,

Z. El Hechmi

Razi Hospital, Psychiatry F, Mannouba, Tunisia

Corresponding author.

Introduction

A history of childhood trauma is reportedly more

prevalent in people suffering from psychosis than in the gen-

eral population. Previous studies linked childhood trauma (CT) to

neurocognitive impairments in schizophrenia (SCZ), but rarely to

theory of mind (TOM) deficits.

Objectives

To investigate the relationship between TOM deficits

and CT in SCZ.

Methods

Fifty-eight outpatients with stable SCZ completed the

Childhood Trauma Questionnaire retrospectively assessing five

types of childhood trauma (emotional, physical and sexual abuse,

and emotional and physical neglect). They also completed an

intention-inferencing task, inwhich the ability to infer a character’s

intentions from information in a short story is assessed.

Results

Our results suggest a relationship between specific kinds

of CT and TOM deficits. A history of childhood physical neglect was

significantly correlated to a worse performance in the intention-

inferencing task (

P

= 0,001). Patients with higher scores of CT denial

also had less correct answers (

P

= 0,035) and more false answers

(

P

= 0,013).

Conclusions

Our results need replication but underline the neces-

sity of investigating psychosocial mechanisms underlying the

development of social cognition deficits, including deficits in TOM.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.660

EW543

Prevalence and predictors of the

metabolic syndrome in patients on

the long term atypical antipsychotic

treatment

I. Popovic

1 ,

, S.

Ð

ukic - Dejanovic

2

, V. Popovic

3

, S. Vladejic

4

1

Specialized Psychiatric Hospital “Gornja Toponica”, Admission

Ward, Gornja Toponica- Niˇs, Serbia

2

Faculty of Medical Sciencies- Kragujevac, Psychiatry, Kragujevac,

Serbia

3

Specialized Psychiatric Hospital “Gornja Toponica”, Addiction Ward,

Gornja Toponica- Niˇs, Serbia

4

Specialized Psychiatric Hospital “Gornja Toponica”, Forensic Ward,

Gornja Toponica- Niˇs, Serbia

Corresponding author.

Objective

We performed a case-control clinical study, which

included 285 long term hospitalized schizophrenic patients, both

gender, treatedwithmonotherapy clozapine, olanzapine or risperi-

done for at least 6 months. Patients with diagnosed metabolic

syndrome according to International Diabetes Federation (IDF)

criteria were classified as cases, while the “controls” were patients

treated with the same antipsychotic drug without the metabolic

syndrome presence. The aim of this research was to determine the

correlation of the studied variables as a potentially risk factors for

the metabolic syndrome presence.

Materials and methods

The following variables were collected:

basic physical parameters (height, weight, waist circumference,

blood pressure), clinical status (BPRS scale and PANSS scale for

schizophrenia), laboratory data (fasting glucose level, serum lipid

levels, C-reactive protein, microalbuminuria), and medical-record

data.

Results

General prevalence of metabolic syndrome was 31,2%,

in patients treated with clozapine 41,3%, olanzapine 34,4% and

risperidone 19%, statistically significant clozapine vs. risperidone

(

P

< 0.05). Predictors of the metabolic syndrome computed by mul-

tivariate logistic regression: - patients treated with olanzapine:

case-history data about diabetes mellitus in close family mem-

ber (OR 14.134, 95% CI 2.724–73.348,

P

= 0.002); hyperlipidemia

in close family member- (OR 53.134, 95% CI 2.768–1019.916,

P

= 0.008; BMI [kg/m

2

] - (OR 1.328, 95% CI 1.105–1.597,

P

= 0.002);

C-reactive protein over the cutoff point of 5 mg/L (OR 4.555,

95% CI 1.057–19.627,

P

= 0.042), and mankind (OR 4.653, 95% CI

1.008–21.479,

P

= 0.049); patients treated with clozapine: diabetes

mellitus in close family member (OR 14.127, 95% CI 2.407–82892,

P

= 0.003); patients treated with risperidone - there were no signif-

icant predictors.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.661